NEW YORK, Dec 14 - Quest Diagnostics, a gene-based medical testing company, said Friday it had made an equity investment in Structural Bioinformatics, extending a relationship that began in 1999.
Terms of the transaction were not disclosed.
“SBI is a technology leader in the large-scale computational generation of protein structures and leads the field in protein-structure database management systems and structural data mining tools,” Jorge Leon, vice president of applied genomics at Quest Diagnostics, said in a statement.
“As the leader in gene-based testing, Quest Diagnostics has accumulated a large database of viral mutations. Together, we can bring to bear advances in information technology to drive advances in patient care,” Leon said.
Quest Diagnostics and SBI formed a strategic alliance in July 1999 to work together to design and market database modules that contain thousands of protein structures. The database modules now contain thousands of forms of viral proteins. The data is derived from viral genotypes taken from patient specimens that have been analyzed by Quest Diagnostics.
Current Variome database modules offer more than 25,000 unique structures of two HIV-1 proteins, reverse transcriptase and protease. These modules give three-dimensional computer representations of the structures of all currently approved HIV-1 drugs docked to the active site of each archived protein.